Curcumin in PCOS

Phase 3

Recruiting

Conditions: Polycystic ovary syndrome.
Polycystic ovarian syndrome

Registration Number: IRCT20091114002709N50

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 72

Inclusion Criteria

The willingness to voluntarily participate in the study
Diagnosis of polycystic ovary syndrome by a specialist physician in the mild to moderate phase
Having impaired glucose tolerance (IGT)
The consumer is just one of the metformin or clomiphene drug groups
Age more than 18 years old
BMI higher than 25 and less than 30 kg/m2

Exclusion Criteria

Change the type and dosage of the drug over the past month
Congenital hormonal disorders, autoimmune diseases, cancer, inflammatory diseases, hyperthyroidism and hypothyroidism, infections, pregnancy or lactation in women, or use of contraceptive pills
The use of multi-vitamin-mineral, omega-3, polyphenolic and antioxidant supplements, as well as the use of anticoagulants such as heparin and warfarin or aspirin, blood cholesterol-lowering drugs (statins), NSAIDs, such as ipobrofen, aspirin and diclofenac, Antihistamines, calcium channel antagonists such as nifedipine, anti-TNF drugs (infliximab, adalimumab and cinnura), glucocorticosteroids (cortisone, prednisolone) and spironolactone during in the past month.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting Blood Sugar. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Fasting Insulin. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;PGC1-a gene expression. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: Real Time RT-PCR.;Sirt1 gene expression. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: Real Time RT-PCR.

Secondary Outcome Measures